![Half of adalimumab patients did not give consent for biosimilar switch, survey reveals - The Pharmaceutical Journal Half of adalimumab patients did not give consent for biosimilar switch, survey reveals - The Pharmaceutical Journal](https://pharmaceutical-journal.com/wp-content/uploads/2022/02/humira-scaled-e1645704431602.jpg)
Half of adalimumab patients did not give consent for biosimilar switch, survey reveals - The Pharmaceutical Journal
![dtw Research, Inc on Twitter: "Humira Introduces New Citrate-Free Formulation in the Q1 2019 Biologics and Non-Biologics for GI Indications @abbvie #dtw #marketHighlights #abbvie #Humira #citratefree #adalimumab #GI #GIIndications #Q12019 ... dtw Research, Inc on Twitter: "Humira Introduces New Citrate-Free Formulation in the Q1 2019 Biologics and Non-Biologics for GI Indications @abbvie #dtw #marketHighlights #abbvie #Humira #citratefree #adalimumab #GI #GIIndications #Q12019 ...](https://pbs.twimg.com/media/D8eCuD8WsAA1vub.jpg:large)
dtw Research, Inc on Twitter: "Humira Introduces New Citrate-Free Formulation in the Q1 2019 Biologics and Non-Biologics for GI Indications @abbvie #dtw #marketHighlights #abbvie #Humira #citratefree #adalimumab #GI #GIIndications #Q12019 ...
![Systematic analysis of injection-site pain and reactions caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus the adalimumab reference product via different delivery methods - GaBI Journal Systematic analysis of injection-site pain and reactions caused by subcutaneous administration of the adalimumab biosimilar FKB327 versus the adalimumab reference product via different delivery methods - GaBI Journal](http://gabi-journal.net/wp-content/uploads/GJ-2020-3-p111-Tab-01.jpg)